{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:20:11Z","timestamp":1787786411333,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202206380049"],"award-info":[{"award-number":["202206380049"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56688-y","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:45:56Z","timestamp":1781271956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["On the value of radiomics in addition to clinical measures in emotional conflict fMRI for predicting sertraline response in major depressive disorder"],"prefix":"10.1038","volume":"16","author":[{"given":"Mingshi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk A.","family":"Marquering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henricus G.","family":"Ruh\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Reneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthan W.A.","family":"Caan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"56688_CR1","unstructured":"Depressive disorder (depression). World Health Organization (2023). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"56688_CR2","doi-asserted-by":"crossref","unstructured":"Klein, et al. Developing Advanced AI Ecosystems to Enhance Diagnosis and Care for Patients with Depression. Stud. Health Technol. Inform. 22, 18\u201322 (2023).","DOI":"10.3233\/SHTI230731"},{"key":"56688_CR3","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 163, 1905\u20131917 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"56688_CR4","doi-asserted-by":"crossref","unstructured":"Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H. & Nierenberg,. A critical review of pharmacotherapy for major depressive disorder. Int. J. Neuropsychopharmacol. 1431, 1417\u20131431 (2011).","DOI":"10.1017\/S1461145711000083"},{"key":"56688_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/JCP.0000000000000950","volume":"38","author":"R Valle-Cabrera","year":"2018","unstructured":"Valle-Cabrera, R. et al. Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial. J. Clin. Psychopharmacol. 38, 454\u2013459 (2018).","journal-title":"J. Clin. Psychopharmacol."},{"key":"56688_CR6","unstructured":"Khouzam, H. R. & Depression Guidelines for Effective Primary Care, Part 2, Treatment. Consultant 360 https:\/\/www.consultant360.com\/content\/depression-guidelines-effective-primary-care-part-2-treatment"},{"key":"56688_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nic.2019.09.006","volume":"30","author":"A Schrantee","year":"2020","unstructured":"Schrantee, A., Ruh\u00e9, H. G. & Reneman, L. Psychoradiological Biomarkers for Psychopharmaceutical Effects. Neuroimaging Clin. N Am. 30, 53\u201363 (2020).","journal-title":"Neuroimaging Clin. N Am."},{"key":"56688_CR8","doi-asserted-by":"crossref","unstructured":"Martinelli, C. & Shergill,. Everything you wanted to know about neuroimaging and psychiatry, but were afraid to ask. BJPsych Adv. 260, 251\u2013260 (2015).","DOI":"10.1192\/apt.bp.114.013763"},{"key":"56688_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062148","volume":"2148","author":"S-G Kang","year":"2020","unstructured":"Kang, S.-G. & Cho,. Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder. Int. J. Mol. Sci. 2148, 2148 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"56688_CR10","doi-asserted-by":"publisher","first-page":"103157","DOI":"10.1016\/j.nicl.2022.103157","volume":"36","author":"AR Gerlach","year":"2022","unstructured":"Gerlach, A. R. et al. MRI predictors of pharmacotherapy response in major depressive disorder. Neuroimage Clin. 36, 103157 (2022).","journal-title":"Neuroimage Clin."},{"key":"56688_CR11","doi-asserted-by":"crossref","unstructured":"Fonzo, et al. Brain regulation of emotional conflict predicts antidepressant treatment response for depression. Nat. Hum. Behav. 1331, 1319\u20131331 (2019).","DOI":"10.1038\/s41562-019-0732-1"},{"key":"56688_CR12","doi-asserted-by":"crossref","unstructured":"Williams, et al. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial. Neuropsychopharmacology 2408, 2398\u20132408 (2015).","DOI":"10.1038\/npp.2015.89"},{"key":"56688_CR13","doi-asserted-by":"crossref","unstructured":"Godlewska, et al. Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex. Int. J. Neuropsychopharmacol. 996, 988\u2013996 (2018).","DOI":"10.1093\/ijnp\/pyy069"},{"key":"56688_CR14","doi-asserted-by":"crossref","unstructured":"Godlewska, B. R., Browning, M., Norbury, R., Cowen, P. J. & Harmer,. Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Transl. Psychiatry 6e957. (2016).","DOI":"10.1038\/tp.2016.130"},{"key":"56688_CR15","doi-asserted-by":"crossref","unstructured":"Lambin, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat. Rev. Clin. Oncol. 762, 749\u2013762 (2017).","DOI":"10.1038\/nrclinonc.2017.141"},{"key":"56688_CR16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2967\/jnumed.118.222893","volume":"495","author":"MEeaItRJNM61 Mayerhoefer","year":"2020","unstructured":"Mayerhoefer, MEeaItRJNM61. et al. Introduction to Radiomics. J. Nucl. Med. 495, 488\u2013495 (2020).","journal-title":"J. Nucl. Med."},{"key":"56688_CR17","doi-asserted-by":"crossref","unstructured":"Wang, et al. Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer\u2019s disease and amnestic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging. Front. Neurosci. 970245, 970245 (2022).","DOI":"10.3389\/fnins.2022.970245"},{"key":"56688_CR18","doi-asserted-by":"publisher","first-page":"e12276","DOI":"10.1016\/j.heliyon.2022.e12276","volume":"8","author":"D Shi","year":"2022","unstructured":"Shi, D. et al. Neuroimaging biomarkers for detecting schizophrenia: A resting-state functional MRI-based radiomics analysis. Heliyon 8, e12276 (2022).","journal-title":"Heliyon"},{"key":"56688_CR19","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/7BWXD","author":"M Chen","year":"2025","unstructured":"Chen, M., Caan, M. W. A., Reneman, L., Marquering, H. A. & Ruh\u00e9, H. G. Radiomics-Based Analysis of Emotional Conflict fMRI Predicts Sertraline Response in Major Depressive Disorder. OSF Registries. https:\/\/doi.org\/10.17605\/OSF.IO\/7BWXD (2025).","journal-title":"OSF Registries"},{"key":"56688_CR20","doi-asserted-by":"crossref","unstructured":"Poirot, et al. Treatment response prediction in major depressive disorder using multimodal MRI and clinical data: Secondary analysis of a randomized clinical trial. Am J Psychiatry 233, 223\u2013233 (2024).","DOI":"10.1176\/appi.ajp.20230206"},{"key":"56688_CR21","doi-asserted-by":"crossref","unstructured":"Khosla, M., Jamison, K., Ngo, G. H., Kuceyeski, A. & Sabuncu,. Machine learning in resting-state fMRI analysis. Magn Reson Imaging 121, 101\u2013121 (2019).","DOI":"10.1016\/j.mri.2019.05.031"},{"key":"56688_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41586-020-2314-9","volume":"582","author":"R Botvinik-Nezer","year":"2020","unstructured":"Botvinik-Nezer, R. et al. Variability in the analysis of a single neuroimaging dataset by many teams. Nature 582, 84\u201388 (2020).","journal-title":"Nature"},{"key":"56688_CR23","doi-asserted-by":"crossref","unstructured":"Nguyen, et al. Patterns of pretreatment reward task brain activation predict individual antidepressant response: Key results from the EMBARC randomized clinical trial. Biol Psychiatry 560, 550\u2013560 (2022).","DOI":"10.1016\/j.biopsych.2021.09.011"},{"key":"56688_CR24","doi-asserted-by":"crossref","unstructured":"Alders, et al. Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI emotional conflict task: A CAN-BIND-1 study. Journal of Affective Disorders 424, 414\u2013424 (2020).","DOI":"10.1016\/j.jad.2019.11.068"},{"key":"56688_CR25","doi-asserted-by":"publisher","unstructured":"Fisher, et al. Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. Journal of Psychopharmacology https:\/\/doi.org\/10.1177\/02698811221089035 (2022).","DOI":"10.1177\/02698811221089035"},{"key":"56688_CR26","doi-asserted-by":"publisher","unstructured":"Elliott, et al. What is the test-retest reliability of common task-functional MRI measures? New empirical evidence and a meta-analysis. Psychological Science https:\/\/doi.org\/10.1177\/0956797620916786 (2020).","DOI":"10.1177\/0956797620916786"},{"key":"56688_CR27","first-page":"841","volume":"848","author":"HRD:Gfepc Khouzam","year":"2007","unstructured":"Khouzam, HRD:Gfepc. Depression: Guidelines for effective primary care, part 2, treatment. The Consultant 848, 841\u2013848 (2007).","journal-title":"The Consultant"},{"key":"56688_CR28","doi-asserted-by":"crossref","unstructured":"Trivedi, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. J Psychiatr Res 23, 11\u201323 (2016).","DOI":"10.1016\/j.jpsychires.2016.03.001"},{"key":"56688_CR29","doi-asserted-by":"crossref","unstructured":"Szegedi, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry 353, 344\u2013353 (2009).","DOI":"10.4088\/JCP.07m03780"},{"key":"56688_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40263-014-0171-5","volume":"28","author":"PA Kudlow","year":"2014","unstructured":"Kudlow, P. A., McIntyre, R. S. & Lam, R. W. Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs. 28, 601\u2013609 (2014).","journal-title":"CNS Drugs"},{"key":"56688_CR31","unstructured":"Bagnis, A. et al. A scoping review of placebo and nocebo responses and effects: insights for clinical trials and practice. Health Psychol. Rev 1\u201339 (2025)."},{"key":"56688_CR32","doi-asserted-by":"crossref","unstructured":"Furukawa, et al. Placebo response rates in antidepressant trials: A systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry 1066, 1059\u20131066 (2016).","DOI":"10.1016\/S2215-0366(16)30307-8"},{"key":"56688_CR33","doi-asserted-by":"crossref","unstructured":"Skvortsova, et al. Placebo effects in the neuroendocrine system: Conditioning of the oxytocin responses. Psychosom Med 56, 47\u201356 (2020).","DOI":"10.1097\/PSY.0000000000000759"},{"key":"56688_CR34","doi-asserted-by":"publisher","unstructured":"Esteban, O. et al. FMRIPrep: a robust preprocessing pipeline for functional MRI. bioRxiv 306951 (2018). https:\/\/doi.org\/10.1101\/306951","DOI":"10.1101\/306951"},{"key":"56688_CR35","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/j.neuroimage.2008.10.055","volume":"45","author":"MW Woolrich","year":"2009","unstructured":"Woolrich, M. W. et al. Bayesian analysis of neuroimaging data in FSL. Neuroimage 45, S173\u2013S186 (2009).","journal-title":"Neuroimage"},{"key":"56688_CR36","doi-asserted-by":"crossref","unstructured":"Singh, S. Machine Learning and Systems Biology in Genomics and Health (Springer Nature, 2022).","DOI":"10.1007\/978-981-16-5993-5"},{"key":"56688_CR37","doi-asserted-by":"crossref","unstructured":"van Griethuysen, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res 77, e104\u2013e107 (2017).","DOI":"10.1158\/0008-5472.CAN-17-0339"},{"issue":"8","key":"56688_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/bioinformatics\/bti171","volume":"21","author":"J Hua","year":"2005","unstructured":"Hua, J., Xiong, Z., Lowey, J., Suh, E. & Dougherty, E. R. Optimal number of features as a function of sample size for various classification rules. Bioinformatics 21 (8), 1509\u20131515 (2005).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56688-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:10:09Z","timestamp":1787785809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56688-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56688"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56688-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.W.A. Caan is a shareholder of Nico-lab International Ltd. H.A. Marquering is a shareholder of Nico-lab International Ltd., TrianecT B.V., and inSteps B.V. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26868"}}